U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07325591) titled 'Efficacy and Safety of Tazbentetol in ALS Participants' on Jan. 06.
Brief Summary: The objectives of this study are to examine the effects of tazbentetol on clinical measures of ALS, patient reported outcomes (PROs), long-term safety and tolerability.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Amyotrophic Lateral Sclerosis
Intervention:
DRUG: Tazbentetol 300 mg once daily
participants in double blind placebo controlled phase will be randomized to received study drug tazbentetol at 300 mg once daily and placebo tablets once daily. Participants in the open-label extension phase will receive the dose determi...